RCS - Ondine Biomedical - NHS Trust up for HSJ Award for Steriwave Use

Ondine Biomedical

12/06/2025 07:00

RNS Number : 4865M

Ondine Biomedical Inc.

12 June 2025

 

12th June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

NHS Trust up for HSJ Award for Steriwave Use

 

Mid Yorkshire Teaching NHS Trust Shortlisted for HSJ Patient Safety Award for Cutting Surgical Infections with Ondine's Steriwave Nasal Photodisinfection

 

 

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that the Mid Yorkshire Teaching NHS Trust (Mid Yorks) has been shortlisted for the prestigious HSJ Patient Safety Awards following the successful implementation of Ondine's Steriwave® nasal decolonization technology.

 

Introduced to reduce surgical site infections (SSI) in patients undergoing hip and knee replacement surgeries, the Steriwave intervention was associated with a remarkable 71% reduction in SSI over a six-month period, along with significant cost savings and improved patient outcomes.

 

Carolyn Cross, CEO of Ondine:

"We would like to congratulate Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorks, and his team for pioneering the introduction of Steriwave in the NHS. Their work has clearly demonstrated the clinical benefits of Steriwave and has sparked interest across NHS hospitals, particularly as antibiotic resistance continues to rise."

 

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust:

"Being named a finalist is a testament to the hard work and dedication of our team. Patient safety is at the heart of everything we do, and we're proud to be recognized at a national level."

 

The shortlisting follows a rigorous judging process conducted by a panel of healthcare and patient safety experts.

 

Steriwave is a non-invasive and painless light-activated antimicrobial therapy that destroys harmful pathogens in the nose-a major source of infection-in minutes. The treatment involves applying the proprietary Steriwave photosensitive agent to each nostril followed by illumination with a specific wavelength of red light. Steriwave is immediately effective against bacteria, viruses, and fungi and does not contribute to antimicrobial resistance, offering a powerful tool in the fight against healthcare-associated infections.

 

Organized by the Health Service Journal (HSJ), the Patient Safety Awards celebrate the teams and individuals going above and beyond to protect patients from harm, reduce risks, and embed a culture of safety across the UK healthcare sector. Winners will be announced at the awards ceremony later this year.

 

 

Enquiries:

​

Ondine Biomedical Inc.
www.ondinebio.com
Carolyn Cross, CEO
+1 604 669 0555
 or via Vane Percy & Roberts
Strand Hanson Limited (Nominated & Financial Adviser)
James Harris, Richard Johnson
+44 (0)20 7409 3494
RBC Capital Markets (Broker)
Kathryn Deegan
+44 (0)20 7653 4000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy
+44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAUAORRVNUNAUR